Anderson B, Shad A T, Gootenberg J E, Sandler S G
Department of Pediatrics, Georgetown University Medical Center, Washington, DC, USA.
Am J Hematol. 1999 Mar;60(3):245-7. doi: 10.1002/(sici)1096-8652(199903)60:3<245::aid-ajh16>3.0.co;2-4.
Alloimmunization to the D blood group antigen following the transfusion of D-positive red blood cells to a D-negative recipient may be prevented in most persons by a prompt and adequate dose of Rho (D) immune globulin (RhIG). Until recently, the only RhIG approved by the US Food and Drug Administration (FDA) for this indication required intramuscular injection, an inconvenient and painful route for the relatively large volume that may be required. We describe the successful prevention of Rh alloimmunization following the unintentional transfusion of D-positive red blood cells to a D-negative infant by the intravenous infusion of WinRho SD, a new RhIG that is FDA-approved for prevention of post-transfusion Rh alloimmunization by intravenous administration. We believe that this more convenient and less painful approach should be the treatment of choice for preventing Rh alloimmunization following the transfusion of D-positive red cells to a D-negative recipient.
对于D阴性受血者输注D阳性红细胞后发生的D血型抗原同种免疫，多数人可通过及时给予足量的Rho（D）免疫球蛋白（RhIG）来预防。直到最近，美国食品药品监督管理局（FDA）批准用于此适应症的唯一RhIG需要肌内注射，对于可能需要的相对大容量而言，这是一种不方便且痛苦的给药途径。我们描述了通过静脉输注WinRho SD成功预防D阴性婴儿意外输注D阳性红细胞后发生的Rh同种免疫，WinRho SD是一种新的RhIG，已获FDA批准可通过静脉给药预防输血后Rh同种免疫。我们认为，这种更方便且痛苦较小的方法应成为预防D阴性受血者输注D阳性红细胞后发生Rh同种免疫的首选治疗方法。
